Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus
about
Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implicationsHematological disorders in patients with systemic lupus erythematosus.Thrombosis and antiphospholipid antibody syndrome during acute Q fever: A cross-sectional study.Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and SafetyTreatment of the antiphospholipid syndrome.Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort studyRenal transplantation dramatically reduces IgA anti-beta-2-glycoprotein I antibodies in patients with endstage renal disease.Antiphospholipid syndrome: an update.Optimizing the use of existing therapies in lupus.Emerging Therapies in Antiphospholipid Syndrome.Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?New Perspectives in Rheumatology: Avoiding Antimalarial Toxicity.Kidney disease in primary anti-phospholipid antibody syndrome.Hydroxychloroquine in systemic lupus erythematosus (SLE).Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome.Antiphospholipid Antibody Syndrome With Valvular Vegetations in Acute Q Fever.Commentary on "The risky business of studying prognosis".Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study.
P2860
Q26998188-9C166E97-11BE-453D-8A8C-E9FF937942DFQ33411323-098E1008-6760-40B3-BCCA-CA7FBB904CA9Q33443797-404054DC-E4C8-48BA-8372-643766B5552DQ33692770-2785D149-DAE2-4CAF-BD67-AD798025FF89Q35308972-3AE9F43B-A9DA-4F2F-8E0F-5437C35ED592Q37228076-1C731FB1-FC50-4ED5-A4E2-F475B64941C3Q37730681-8688C993-3215-44D8-9597-0AE1CF92E1A1Q38410376-84D8AE14-2CF0-4169-A082-EA3CB02089BFQ38425824-8924FFB9-C35E-48CE-A792-69FDD89382D9Q38782057-46D3C80C-6D8C-470F-BBDC-DA6A2B28E71AQ38794847-53494DED-6A27-4ADA-A694-FE9718461EBDQ38816742-8F252575-D257-4840-A106-F1AEAAEA85E2Q38934375-3EC56603-884B-46C8-9DE2-AA1DC457B1AFQ39031764-24F5E7AA-F990-4B8A-8255-40B386C6D6A1Q39608521-6CDB64F2-0E2D-4DC4-AE27-A7A30C3B44DFQ40130285-B6844533-5951-46E8-B466-B9C3F9F10A47Q42732278-A3A6C90D-0AA8-4306-B03E-3D1A41291C5CQ50065429-6DD66783-1AAC-4978-BC00-953119307DD0
P2860
Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hydroxychloroquine use is asso ...... n systemic lupus erythematosus
@en
Hydroxychloroquine use is asso ...... systemic lupus erythematosus.
@nl
type
label
Hydroxychloroquine use is asso ...... n systemic lupus erythematosus
@en
Hydroxychloroquine use is asso ...... systemic lupus erythematosus.
@nl
prefLabel
Hydroxychloroquine use is asso ...... n systemic lupus erythematosus
@en
Hydroxychloroquine use is asso ...... systemic lupus erythematosus.
@nl
P2860
P921
P356
P1476
Hydroxychloroquine use is asso ...... n systemic lupus erythematosus
@en
P2093
Anna Broder
Chaim Putterman
P2860
P356
10.3899/JRHEUM.120157
P407
P577
2012-08-01T00:00:00Z